Verisk Analytics, Inc. (VRSK) Stock Analysis
Is VRSK a good investment?
Verisk Analytics, Inc. (VRSK) has a Plutrex AI rating of 65.0/100 as of October 11, 2026, indicating a Buy consensus. The stock is halal-compliant per AAOIFI standards. Key strength: Elite profitability moat: Operating margin 45.1% is 63% above the industry average of 27.7%; net margin 28.2% is 48.7% above peers; FCF of $1.237B ($4.40/share) funds all capital needs independently — reflects near-monopoly positioning in insurance analytics with high switching costs and recurring subscription revenue. Main concern: AccuLynx court-mandated acquisition (~$2.35B, ~1.9x annual FCF of $1.237B) UNCHANGED and unresolved — forces integration of an unwanted asset at premium on already negative-equity balance sheet, will increase gross debt meaningfully, diverts FCF from buybacks/dividends, introduces execution risk management did not choose, and is the single largest binary risk overhang preventing upgrade to Buy.
Investment Summary
Verisk Analytics (VRSK) is an exceptional-quality business trading at a stretched valuation after a 5.0% price rebound to $177.63 over the past 14 days — moving the stock further above our prior entry zone of $163-$170 and making the risk/reward less compelling. The core thesis is unchanged: VRSK operates one of the most profitable data analytics franchises in the world, with a 45.1% operating margin (63% above the industry average of 27.7%), a 28.2% net margin (48.7% above peers at 19.0%), and $1.237B in annual free cash flow. These are genuinely elite metrics. However, the valuation has moved in the wrong direction: P/E is now 27.29x (up from 26.0x prior), and PEG has risen to 2.51x (up from 2.39x prior), now 27.8% above the industry average PEG of 1.96x — all while VRSK's 5-year forward EPS growth of 10.89% remains 35.8% below peers' 16.96%. The stock is now trading above our prior upper entry bound of $170, making the current price less attractive. The AccuLynx court-mandated acquisition (~$2.35B, ~1.9x annual FCF) remains unresolved, introducing binary risk on leverage and capital allocation. News is constructive (79.4/100 sentiment, 8 of 12 headlines positive) — AI integration in insurance fraud detection and rating upgrades are genuine positives — but do not resolve the fundamental PEG premium or AccuLynx overhang. HOLD maintained; wait for pullback to $163-$170 entry zone.
Key Strengths
- Elite profitability moat: Operating margin 45.1% is 63% above the industry average of 27.7%; net margin 28.2% is 48.7% above peers; FCF of $1.237B ($4.40/share) funds all capital needs independently — reflects near-monopoly positioning in insurance analytics with high switching costs and recurring subscription revenue
- AI integration and structural demand tailwind: 'Truepic Brings Verified Visual Evidence to Verisk's ClaimSearch® Workflow' (neutral headline, positive content — expanding AI capabilities in claims fraud detection) combined with 'AI-Led Growth & Strong Cash Generation Support VRSK Amid High Debt' signals Verisk is successfully embedding AI into its data products, potentially expanding addressable market in insurance analytics beyond legacy risk modeling
- Analyst consensus conviction intact: $231.60 target (30.4% upside from $177.63) with 'All You Need to Know About Verisk Rating Upgrade to Buy' headline confirms institutional buy-side re-rating momentum; 'Why Verisk Analytics is a Top Growth Stock for the Long-Term' reflects durable franchise recognition
Key Concerns
- AccuLynx court-mandated acquisition (~$2.35B, ~1.9x annual FCF of $1.237B) UNCHANGED and unresolved — forces integration of an unwanted asset at premium on already negative-equity balance sheet, will increase gross debt meaningfully, diverts FCF from buybacks/dividends, introduces execution risk management did not choose, and is the single largest binary risk overhang preventing upgrade to Buy
- Valuation has WORSENED since prior report: PEG now 2.51x (up from 2.39x), P/E now 27.29x (up from 26.0x) — stock rallied 5.0% to $177.63, now above prior upper entry bound of $170, while the 5-year forward EPS growth of 10.89% remains 35.8% below peers' 16.96% and revenue growth of 4.4% remains 54% below industry 9.56%; paying more for less growth than 14 days ago
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
VRSK's fundamentals are a study in contrasts: world-class profitability metrics versus below-average growth at an above-average price. Profitability: Gross margin 59.8% (below peers' 66.6% — the one profitability gap), operating margin 45.1% (vs. industry 27.7% — 63% premium), net margin 28.2% (vs. industry 19.0% — 48.7% premium), ROE 444.1% (mathematically distorted by negative book equity from cumulative buybacks, not operationally meaningful in isolation). FCF of $1.237B is the cornerstone — genuine economic earnings power. Valuation: P/E 27.29x on 10.89% 5-year EPS growth yields a PEG of 2.51x — 2.5x the fair-value PEG threshold of 1.0x. Even at a generous moat-premium PEG of 1.5x, fair value is ~$105-$115, well below $177.63. Analyst consensus target of $231.60 implies 30.4% upside, driven by sell-side optimism rather than strict intrinsic value analysis. Growth: Revenue growth 4.4% (vs. industry 9.56% — 54% discount); historical EPS growth -3.4% (vs. industry +0.29%); forward EPS growth 12.73% next year (vs. industry 17.32% — 26.5% discount); 5-year EPS CAGR 10.89% (vs. industry 16.96% — 35.8% discount). VRSK is the slowest grower in the peer group on every metric. Health: Cash $552.2M, FCF $1.237B, D/E N/A (negative equity from buybacks — true leverage obscured, creates financial complexity vs. peers with near-zero D/E). The business earns its premium on profitability but does not justify a growth premium.
News Sentiment
Verisk Analytics is quietly building what could be one of the most important data empires in the insurance industry — and Wall Street is starting to take notice. The company just scored a ratings upgrade to Buy, with analysts pointing to its massive cash generation and growing artificial intelligence capabilities as key reasons to own the stock for the long haul. A particularly interesting development: Verisk just partnered with Truepic to bring verified visual evidence directly into its ClaimSearch insurance fraud detection system — think of it as giving insurance adjusters a 'truth filter' for photos and videos submitted during claims. That's the kind of AI integration that could meaningfully expand Verisk's dominance in a market where fraud costs the industry tens of billions annually. Meanwhile, the company continues to generate over $1.2 billion in free cash flow annually, giving it financial firepower that most competitors can only dream about. The stock even made the 'Top 25 High-Growth Dividend Stocks' list for October 2026, underscoring its reputation as a reliable compounder. The main caution flag? A headline warning that 'higher debt levels and rising operational costs present margin pressure risks' — a reminder that Verisk isn't without challenges, particularly with a court-mandated acquisition looming. Still, for long-term investors, Verisk's combination of AI momentum, insurance analytics dominance, and strong cash generation makes it a name worth watching — just at the right price.
Risk Assessment
PRIMARY RISK: AccuLynx court-mandated acquisition (~$2.35B) remains the dominant binary risk — if forced to close at $2.35B on a negative-equity balance sheet with $1.237B annual FCF, VRSK would need ~1.9 years of all FCF to service this single acquisition, eliminating buybacks and dividends in the interim, and materially increasing gross debt on an already complex balance sheet. SECONDARY RISK: Valuation is not a margin-of-safety entry at $177.63 — PEG 2.51x means any forward EPS growth shortfall (from 10.89% target) directly destroys the multiple thesis; peers growing 16.96% would attract capital rotation away from VRSK if growth re-acceleration fails to materialize. TERTIARY RISK: 'Higher debt levels and rising operational costs present margin pressure risks' (per news analysis) — if the 45.1% operating margin compresses toward peer average of 27.7%, the entire valuation premium collapses. MITIGATION: Wait for pullback to $163-$170 entry zone (6-8% below current price) which brings PEG to approximately 2.30-2.38x and provides a modest margin of safety; limit position to 3% of portfolio to contain AccuLynx binary risk; stop at $155.00 limits downside to 6.9% from entry midpoint $166.50.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is VRSK a halal stock?
Yes, Verisk Analytics, Inc. (VRSK) is halal-compliant per AAOIFI standards as of the latest quarterly review.
What is Plutrex's AI rating for VRSK?
Verisk Analytics, Inc. (VRSK) has a Plutrex AI rating of 65.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is VRSK a good investment?
According to Plutrex AI, VRSK has a Buy rating (65.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in VRSK?
US stocks like VRSK can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in VRSK?
Plutrex AI identifies the main risks for VRSK by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.